Compare FPI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | PHAR |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 1.2B |
| IPO Year | 2013 | 2020 |
| Metric | FPI | PHAR |
|---|---|---|
| Price | $10.44 | $12.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 311.0K | 10.4K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $52,178,000.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $1,048.00 | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $9.54 |
| 52 Week High | $13.23 | $21.34 |
| Indicator | FPI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 31.19 |
| Support Level | $10.14 | $11.43 |
| Resistance Level | $10.58 | $17.41 |
| Average True Range (ATR) | 0.18 | 0.53 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 45.04 | 15.28 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.